RDHL

Talicia® (omeprazole magnesium, amoxicillin and rifabutin)

Helicobacter pylori (H. pylori)

Quarterly Sales (Approved)

Exp Date

March 5, 2021 (Est)

Amp Volatility Score

N/A

Catalyst Info & Data Links

MECHANISM OF ACTION / RATIONALE

  • TALICIA is a combination of antibacterial drugs (rifabutin, amoxicillin) and a proton pump inhibitor (omeprazole as omeprazole magnesium), an antisecretory drug [see Microbiology (12.4)].

  • Amoxicillin acts through the inhibition of cell wall biosynthesis that leads to the death of bacteria. Rifabutin inhibits DNA-dependent RNA polymerase in susceptible microorganisms but not in mammalian cells.

  • Learn more HERE

MARKET

  • About 30 to 40 percent of people in the United States get an H. pylori infection (Learn more HERE). 

Updated by HC

#RDHL, #Talicia, #omeprazole magnesium, #amoxicillin, #rifabutin, #Helicobacter pylori, #gastrointestinal, #bacteria, #inflammation, #GI

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

RDHL - RedHill Biopharma Provi...

Summary: Q3/2020 net revenues of approximately $21 million, with gross profit of $10.6 million, or approximately 51%, up from $6.7 million and approximately 32% in Q2/2020 Strong growth for Talicia® w...

RDHL - Positive Recommendation...

#RDHL announced that its U.S. Phase 2 study with #opaganib (#Yeliva®, #ABC294640)1 in patients hospitalized with severe #COVID-19 pneumonia, has successfully passed the first scheduled independent Saf...

RDHL - Opaganib COVID-19 Study...

#RDHL announced that the "U.S. Phase 2 study with opaganib (Yeliva®, ABC294640)1 in patients hospitalized with severe COVID-19 pneumonia has passed its second pre-scheduled safety review by the indepe...

RDHL - Brazil Approves RedHill...

#RDHL announced "approval from the Brazilian Health Regulatory Agency (ANVISA) for its ongoing global Phase 2/3 study evaluating opaganib1 in patients hospitalized with severe COVID-19 pneumonia. Opag...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon